Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

Home Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma

/ Publications

Share the Post

About the Author

Related Posts

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)
Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology

Comments

Comments are closed.